Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers

Summary

Wellderly Brain is a randomized, direct-to-participant trial evaluating whether a virtually delivered, multidomain lifestyle coaching intervention can favorably impact plasma biomarkers of Alzheimer's disease (AD) in adults aged 60-80 with APOE4 positivity or elevated polygenic risk. Participants are recruited through 23andMe and enrolled via the MyDataHelps platform. Following genetic eligibility screening, 1,200 participants will be randomized to either a digital lifestyle coaching arm (UCardia) or an education-only control arm. The intervention consists of 16 virtual coaching sessions delivered over 52 weeks. All participants will wear an Oura Ring for continuous health monitoring and provide dried blood samples at baseline, 6 months, and 12 months for plasma p-tau217 and proteomic profiling via the NULISAseq CNS Disease Panel. Saliva samples will be collected for epigenetic aging analysis. The study duration is 14-16 months per participant.

Interventions

• Education · BEHAVIORAL

  Treatment group will recieve 16 virtual lifestyle coaching sessions with a certified wellness coach over the course of 52 weeks. Education will focus on activity and sleep (with guidance from Oura ring) and anti inflammatory diet.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Current 23andMe Research participant with APOE4 positivity genetic variant
* Age 60 to 80 at time of consent
* Have access to an Android or Apple iPhone smartphone device and able to download study apps
* Lives in the United States and able to send and receive US Mail
* Able and willing to perform a self-administered saliva test at screening\*for organic outreach only.
* Able and willing to perform a self-administered finger prick blood collection at three time points throughout the study.

Exclusion Criteria:

* Non-English speaking
* Lives outside of the United States
* Currently taking or planning on taking GLP-1 medications (Exenatide, Liraglutide, Albiglutide, Dulaglutide, Semaglutide or Tirzepatide) within the next 12 months
* Established diagnosis of Mild Cognitive Impairment, Alzheimer's Disease or other Neurodegenerative Disease (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Multiple Sclerosis or Frontotemporal Dementia).
* Current or past Oura Ring user (any Oura Ring use in the last 12 months)

Sites (1)

• Scripps Translational Research Institute, La Jolla, California